ECONOMIC-EVALUATION OF STANDARD HEPARIN AND ENOXAPARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN ELECTIVE HIP-SURGERY

M Drummond; M Aristides; L Davies; C Forbes

ECONOMIC-EVALUATION OF STANDARD HEPARIN AND ENOXAPARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN ELECTIVE HIP-SURGERY

M Drummond, M Aristides, L Davies, C Forbes

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

Deep vein thrombosis (DVT) is a common complication in patients undergoing elective hip surgery. Because of the associated risk of pulmonary embolism, prophylaxis with standard (unfractionated) heparin is becoming increasingly important. Recent clinical trials have shown a low molecular weight form of heparin, enoxaparin, to be more effective than standard heparin in preventing DVT, but the new drug is also more expensive. Data on clinical effectiveness and cost were combined in an economic evaluation of the two regimens. It was found that prophylaxis with enoxaparin would he expected to lead to a net saving of pound 20 per patient. The economic results are sensitive to the costs of enoxaparin, the costs of drug administration and the probability of false clinical diagnosis of DVT or pulmonary embolism.

Original language	English
Pages (from-to)	1742-1746
Number of pages	5
Journal	British Journal of Surgery
Volume	81
Issue number	12
Publication status	Published - Dec 1994

Keywords

MOLECULAR-WEIGHT HEPARIN
UNFRACTIONATED HEPARIN
ORTHOPEDIC-SURGERY
COST-EFFECTIVENESS
VENOUS THROMBOSIS
PREVENTION
TRIAL
REPLACEMENT

Cite this

@article{aa0c911da7ac41528e6302c15c595dc3,

title = "ECONOMIC-EVALUATION OF STANDARD HEPARIN AND ENOXAPARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN ELECTIVE HIP-SURGERY",

abstract = "Deep vein thrombosis (DVT) is a common complication in patients undergoing elective hip surgery. Because of the associated risk of pulmonary embolism, prophylaxis with standard (unfractionated) heparin is becoming increasingly important. Recent clinical trials have shown a low molecular weight form of heparin, enoxaparin, to be more effective than standard heparin in preventing DVT, but the new drug is also more expensive. Data on clinical effectiveness and cost were combined in an economic evaluation of the two regimens. It was found that prophylaxis with enoxaparin would he expected to lead to a net saving of pound 20 per patient. The economic results are sensitive to the costs of enoxaparin, the costs of drug administration and the probability of false clinical diagnosis of DVT or pulmonary embolism.",

keywords = "MOLECULAR-WEIGHT HEPARIN, UNFRACTIONATED HEPARIN, ORTHOPEDIC-SURGERY, COST-EFFECTIVENESS, VENOUS THROMBOSIS, PREVENTION, TRIAL, REPLACEMENT",

author = "M Drummond and M Aristides and L Davies and C Forbes",

year = "1994",

month = dec,

language = "English",

volume = "81",

pages = "1742--1746",

journal = "British Journal of Surgery",

issn = "0007-1323",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - ECONOMIC-EVALUATION OF STANDARD HEPARIN AND ENOXAPARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN ELECTIVE HIP-SURGERY

AU - Drummond, M

AU - Aristides, M

AU - Davies, L

AU - Forbes, C

PY - 1994/12

Y1 - 1994/12

N2 - Deep vein thrombosis (DVT) is a common complication in patients undergoing elective hip surgery. Because of the associated risk of pulmonary embolism, prophylaxis with standard (unfractionated) heparin is becoming increasingly important. Recent clinical trials have shown a low molecular weight form of heparin, enoxaparin, to be more effective than standard heparin in preventing DVT, but the new drug is also more expensive. Data on clinical effectiveness and cost were combined in an economic evaluation of the two regimens. It was found that prophylaxis with enoxaparin would he expected to lead to a net saving of pound 20 per patient. The economic results are sensitive to the costs of enoxaparin, the costs of drug administration and the probability of false clinical diagnosis of DVT or pulmonary embolism.

AB - Deep vein thrombosis (DVT) is a common complication in patients undergoing elective hip surgery. Because of the associated risk of pulmonary embolism, prophylaxis with standard (unfractionated) heparin is becoming increasingly important. Recent clinical trials have shown a low molecular weight form of heparin, enoxaparin, to be more effective than standard heparin in preventing DVT, but the new drug is also more expensive. Data on clinical effectiveness and cost were combined in an economic evaluation of the two regimens. It was found that prophylaxis with enoxaparin would he expected to lead to a net saving of pound 20 per patient. The economic results are sensitive to the costs of enoxaparin, the costs of drug administration and the probability of false clinical diagnosis of DVT or pulmonary embolism.

KW - MOLECULAR-WEIGHT HEPARIN

KW - UNFRACTIONATED HEPARIN

KW - ORTHOPEDIC-SURGERY

KW - COST-EFFECTIVENESS

KW - VENOUS THROMBOSIS

KW - PREVENTION

KW - TRIAL

KW - REPLACEMENT

M3 - Article

SN - 0007-1323

VL - 81

SP - 1742

EP - 1746

JO - British Journal of Surgery

JF - British Journal of Surgery

IS - 12

ER -